P0CB16 AF NFT

Putative disease resistance protein At4g19050

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeiate3di4t3de7pj24xys4pr2jsoqgsasxbkbxojs6pnoxrt47ppzu/metadata.json
IPFS of structure file: 
bafybeie6smaxzrxoeltkeapfwisvdzc3nju4kblh2luft37acmlnz2gxli/AF-P0CB16-F1-model_v2.pdb
First NFT owner address (eip-55): 
0xf7Ea384D3b95C3A242403Fdf8e5bA55488D27a6b
First NFT owner address (bech32): 
genesis17l4rsnfmjhp6ysjq8l0cuka92jydy7ntfnaf42
Current NFT ID #105241 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
105241
Accession (UniProt):
P0CB16
Name::
Putative disease resistance protein At4g19050
Experimental Method:
Predicted structure
Sequence source:
ARABIDOPSIS THALIANA

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT P0CB16 research and analysis (ICN3D with VR)

FASTA sequences

>sp|P0CB16|DRL25_ARATH Putative disease resistance protein At4g19050 OS=Arabidopsis thaliana OX=3702 GN=At4g19050 PE=3 SV=2 MEKQDQTSREEILKKIMDSLGQDGVPSKTVLVGEAGIGKTWLAKEVSQRVTQEKYNVLWLHLNKKIEDEKSLYEILAAQLSIIYEFEEGEEPDELDYPLESLKEKIKEEMIKHKKDNLLLILDDEGSMTTEEDVMQELNLQDFLKEYSAVKILVTRRDEREEKESTTIKVGPLTEKESLDLLHDAEDLLTSFTSEDWPVLLKRLCDNKEIKEPTLMSCILSKSKGLPAAIVVLIKSLNSIKSMSAKQRKIFKELILSSKSLDEAAASKNAIDRSRYNPVLQLSYELLKPDETVKRPVIACFWHILDFYKYSGCAYYRDLIVHWMLEGYFDPVKSVDKAYQEGHSILMDFMNRGILKIQEDNMVVPEFSMSNLLDLQDCGFFGRSSLGFDRVYGGDKRKGLGKIILIDDMIQTIQSKKKNITTIIASGNRLRREVHGKFFEKPEMQDLEVVVLFEPTFHELVLSLSKLKKLRVLVIRDCDLIDNIDKLSGLQGLHVLEVSGASSLVNIPDDFFKNMTQLQSLNLSGLAIKSSPSTIEKLSMLRCFILRHCSELQDLPNFIVETRKLEVIDIHGARKLESYFDRVKDWKDYKGKNKNFAQLQLLEHLDFSETKIIRLPIFHLKDSTNDFSTMPILTRLLLRNCTRLKRLPQLRPLTNLQILDACGATDLVEMLEVCLEEKKELRILDMSKTSLPELADTIADVVNLNKLLLRNCSLIEELPSIEKLTHLEVFDVSGCIKLKNINGSFGEMSYLHEVNLSETNLSELPDKISELSNLKELIIRKCSKLKTLPNLEKLTNLEIFDVSGCTELETIEGSFENLSCLHKVNLSETNLGELPNKISELSNLKELILRNCSKLKALPNLEKLTHLVIFDVSGCTNLDKIEESFESMSYLCEVNLSGTNLKTFPELPKQSILCSSKRIVLADSSCIERDQWSQIKECLTSKSEGSSFSNVGEKTREKLLYHGNRYRVIDPEVPLNIDIVDIKRSTDLKTEYIAKAEYVSIAENGSKSVSSLFDELQMASVKGCWVERCKNMDVLFESDEQLEKEKSSSPSLQTLWISNLPLLTSLYSSKGGFIFKNLKKLSVDCCPSIKWLFPEIPDNLEILRVKFCDKLERLFEVKAGELSKLRKLHLLDLPVLSVLGANFPNLEKCTIEKCPKLKAREDEPRIGARITDEISEDQPHKNTIGPETQTPTQPTKATDTV